Table 1.
Demographic and clinical characteristics of the PAD cohort.
| NaNO3 (n=13) | Placebo (n=8) | p-value | |
|---|---|---|---|
| Age (years) | 73±9 | 69±10 | 0.32 |
| Sex (Male/Female) | 6/7 | 6/2 | 0.20 |
| Body mass index (kg/m2) | 29.2±5.9 | 28.1±3.6 | 0.63 |
| Systolic blood pressure (mmHg) | 136±15 | 132±13 | 0.46 |
| Diastolic blood pressure (mmHg) | 72±9 | 77±10 | 0.30 |
| Ankle-brachial index | 0.76±0.21 | 0.81±0.14 | 0.57 |
| Previous revascularization | 12 (92) | 6 (75) | 0.34 |
| Coronary artery disease | 3 (23) | 0 (0) | 0.65 |
| Type II diabetes mellitus | 4 (31) | 2 (25) | 0.89 |
| Use of a statin | 12 (92) | 7 (88) | 0.78 |
| Use of ACE inhibitors or ARBs | 6 (46) | 2 (25) | 0.62 |
| Use of beta-blocker | 6 (46) | 3 (38) | 0.83 |
| Use of calcium channel blocker | 5 (38) | 2 (25) | 0.76 |
| Use of anticoagulants | 6 (46) | 2 (25) | 0.62 |
| Use of insulin | 2 (15) | 1 (13) | 0.97 |
Data are mean±standard deviation or n (%). NaNO3=sodium nitrate group; ACE=angiotensin converting enzyme; ARB=angiotensin receptor blocker. Groups were compared using an independent samples t-test or chi-squared analysis when appropriate.